[Broncholytic effect of Atrovent in comparison with a combination preparation in obstructive lung diseases].
D000328:Adult; D000368:Aged; D001532:Atropa belladonna / Q000627:therapeutic use; D001285:Atropine / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002110:Caffeine / Q000627:therapeutic use; D004338:Drug Combinations; D004809:Ephedrine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000627:therapeutic use; D010619:Phenazines / Q000627:therapeutic use; D008517:Phytotherapy; D010946:Plants, Medicinal; D010947:Plants, Toxic; D013806:Theophylline / Q000627:therapeutic use; D014326:Tropanes / Q000627:therapeutic use*
D001993:Bronchodilator Agents; D004338:Drug Combinations; D010619:Phenazines; D014326:Tropanes; D002110:Caffeine; D001285:Atropine; D013806:Theophylline; D010208:Papaverine; D004809:Ephedrine
Untersuchungen der broncholytischen Wirkung von Atrovent im Vergleich zu einem Kombinationspräparat bei obstruktiven Lungenerkrankungen